Invivyd, Inc. Invivyd, Inc.

Invivyd, Inc.

IVVD

Rank in Stocks #17035
Adagio Therapeutics, Inc., a biopharmaceutical firm in its clinical development... Adagio Therapeutics, Inc., a biopharmaceutical firm in its clinical development phase, operates within the United States, specializing in the discovery, progression, and marketing of antibody-derived solutions for infectious diseases. The company's leading drug candidate, ADG20 (adintrevimab), is a neutralizing antibody currently undergoing Phase 3 clinical investigation for both the management and prevention of coronavirus disease. Adagio Therapeutics maintains collaborative agreements with Adimab, LLC to facilitate the identification and enhancement of its exclusive antibodies. Furthermore, it partners with the Scripps Research Institute to conduct studies aimed at uncovering potential vaccine solutions for the prophylaxis, detection, or therapy of influenza or beta coronaviruses. Incorporated in 2020, the company's base of operations is in Waltham, Massachusetts.
Share Price
$0.5673
Last synced: 2026-11-12
Market Cap
$181.78M
Change (1 day)
-5.34%
Change (1 year)
-77.58%
Country

Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this

Category

Healthcare
EPS for Invivyd, Inc. (IVVD)
EPS as of June 2026 TTM: $-0.39
According to Invivyd, Inc.'s latest financial reports, its current EPS (TTM) is $-0.39. At the end of 2025 the company had an EPS of $-0.30, an increase over its 2024 EPS of $-1.43.
EPS history for Invivyd, Inc. from 2020 to 2026
EPS at the end of each year
Year EPS Change
2026 (TTM) $-0.39 30.00%
2025 $-0.30 -79.02%
2024 $-1.43 -20.99%
2023 $-1.81 -16.59%
2022 $-2.17 2.84%
2021 $-2.11 257.63%
2020 $-0.59 0.00%
EPS for similar companies or competitors
Company EPS EPS Difference Country
$-0.89 128.21%
US
$15.66 -4,115.38%
US
$-7.07 1,712.82%
US
$-5.29 1,256.41%
AU
$12.73 -3,364.67%
BE

Questions about Invivyd, Inc.'s earnings per share (EPS)

What is Invivyd, Inc.'s earnings per share (EPS)?

Invivyd, Inc.'s earnings per share (EPS) over the last twelve months is $-0.39, as of Jun 2026.

What was Invivyd, Inc.'s earnings per share (EPS) in 2025?

In 2025, Invivyd, Inc.'s earnings per share (EPS) was $-0.30, compared with $-1.43 in 2024.

How has Invivyd, Inc.'s earnings per share (EPS) changed since 2020?

From 2020 to 2025, Invivyd, Inc.'s earnings per share (EPS) was highest in 2025 ($-0.30) and lowest in 2022 ($-2.17).

How does Invivyd, Inc.'s earnings per share (EPS) compare with similar companies?

Invivyd, Inc.'s earnings per share (EPS) ($-0.39) is higher than that of 3 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with $15.66.